Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic mice.
Endothelin-1 (ET-1) exhibits potent proinflammatory and profibrotic properties. Moreover, inflammation is a potent stimulus for inducible NO synthase (iNOS), which has been shown to contribute to cardiac injury. We thus hypothesized that ET-1-induced cardiac injury is attenuated by concomitant lack of iNOS. We established crossbred animals of ET-1 transgenic mice (ET+/+) and iNOS knockout mice (iNOS-/-). At 13 months of age, mice were allocated according to their genotype to one of 4 study groups: wild type (WT) controls (n=8); ET-1 transgenic (ET+/+) mice (n=10); iNOS knockout (iNOS-/-) mice (n=7); and crossbred (ET+/+ iNOS-/-) mice (n=15). Left ventricular function was determined in vivo by using a tip catheter. Animals were subsequently euthanized and hearts were harvested for weight assessment and histologic evaluation. No cardiac hypertrophy was present, as evidenced by similar mean cardiac weight and myocyte diameter in all groups. Cardiac perivascular fibrosis was significantly increased in ET+/+ and iNOS-/- groups versus WT, whereas ET+/+ iNOS-/- mice did not differ from WT. Regarding left ventricular function, plasma B-type natriuretic peptide was elevated in ET+/+ and iNOS-/- mice, but again in crossbred animals this effect was blunted. Heart catheterization revealed a significantly increased stiffness constant in both ET-overexpressing groups versus WT, but this increase was significantly attenuated in the ET+/+iNOS-/- group versus the ET+/+ group. Parameters indicating systolic heart failure (EF, cardiac output), however, were not different between all study groups. Our study demonstrates that ET transgenic mice develop left ventricular stiffening with subsequent diastolic dysfunction in a slow, age-dependent manner. Additional knock out of iNOS significantly attenuates cardiac injury. We thus conclude that ET-1-induced cardiac injury is at least partially mediated by iNOS.
Center for Cardiovascular Research, Department of Pharmacology and Toxicology, Charite, Hessische Str. 3-4, Berlin 10115, Germany.
Philipp
P
Kalk
Dirk
D
Westermann
Sophia
S
Herzfeld
Katharina
K
Relle
Thiemo
T
Pfab
Christian
C
Bauer
Carsten
C
Tschöpe
Johannes-Peter
JP
Stasch
Berthold
B
Hocher
D000375:Aging / Q000502:physiology; D000818:Animals; D003971:Diastole / Q000235:genetics / Q000502:physiology*; D019332:Endothelin-1 / Q000235:genetics / Q000502:physiology*; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009206:Myocardium / Q000473:pathology; D020097:Natriuretic Peptide, Brain / Q000097:blood; D052247:Nitric Oxide Synthase Type II / Q000172:deficiency* / Q000235:genetics; D018487:Ventricular Dysfunction, Left / Q000209:etiology* / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*
D019332:Endothelin-1; D020097:Natriuretic Peptide, Brain; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse